68Ga-FAPI-04

DRUG6 trials

Sponsors

First Affiliated Hospital of Fujian Medical University, Peking Union Medical College Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Peking University Cancer Hospital & Institute

Conditions

Breast CancerEndometrial CancerFAPIFibrosisHepatocellular CarcinomaLiver FibrosisOral CarcinomaOvarian Cancer

Early Phase 1

68Ga-FAPI PET/CT in Liver Fibrosis Patients

First Affiliated Hospital of Fujian Medical UniversityLiver Fibrosis, Positron Emission Tomography

Start: 2020-09-01End: 2023-12-30Target: 50Updated: 2020-09-03

68Ga-FAPI PET/CT in Patients With Various Fibrotic Disease

First Affiliated Hospital of Fujian Medical UniversityFibrosis, Positron-Emission Tomography

Start: 2021-04-01End: 2024-04-01Target: 500Updated: 2023-09-21

68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma

Peking Union Medical College HospitalOral Carcinoma

Start: 2021-04-01End: 2022-12-01Target: 30Updated: 2022-10-28

Unknown Phase

68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With Immunotherapy

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRectal Cancer

Start: 2023-06-20End: 2024-07-31Target: 20Updated: 2023-08-21

Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

CompletedNCT07553741

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBreast Cancer

Start: 2025-04-01End: 2026-04-01Updated: 2026-04-28

68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors

Not yet recruitingNCT07639801

Peking University Cancer Hospital & InstituteEndometrial Cancer, FAPI, Hepatocellular Carcinoma +4

Start: 2026-06-01End: 2026-12-31Target: 20Updated: 2026-06-10

Related Papers

Prospective comparison of [<sup>68</sup>Ga]Ga-FAPI-04 PET/MRI, [<sup>18</sup>F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer.

2026-07-23